ChlebowskiRTGrosvenorMBBernhardNH, Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol1989; 84: 1288–93.
2.
SantangeloWCKrejsGJ. Gastrointestinal manifestations of the acquired immunodeficiency syndrome. Am J Med Sci1986; 292: 328–34.
3.
SmithPDLaneCManischewitzJF, Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med1988; 108: 328–33.
4.
RolstonKVRodriguezSHernandezM, Diarrhea in patients infected with the human immunodeficiency virus. Am J Med1989; 85: 137–8.
5.
ConnollyGMDrydenMSShansonDC, Cryptosporidial diarrhoea in AIDS and its treatment. Gut1988; 29: 593–7.
6.
RosenbergJM. Octreotide: A synthetic analog of somatostatin. Drug Intell Clin Pharm1988; 22: 748–53.
7.
WilliamsNSCooperJCAxonATRKingRFGJBarkerM. Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br Med J1984; 289: 1027–8.
8.
SantangeloWCOdorisioTMKimJGSeverinoGKrejsGJ. Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med1985; 103: 363–7.
9.
EdwardsCCannPAReadNW, Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea. Gut1986; 27: 581–6.
10.
KatzMDErstadBLRoseC. Treatment of severe cryptosporidium-related diarrhea with octreotide in a patient with AIDS. Drug Intell Clin Pharm1988; 22: 134–6.
11.
CookDJKeltonJGStaniszAMCollinsSM. Somatostatin treatment for cryptosporidial diarrhea in a patient with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med1988; 108: 708–9.
12.
RobinsonENFogelR. SMS 201–995, a somatostatin analogue, and diarrhea in the acquired immunodeficiency syndrome (AIDS) (letter). Ann Intern Med1988; 109: 680–1.
13.
FüeblHSZollerWGKochenMM, Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201–995. Klin Wochenschr1989; 67: 452–5.
14.
PleweGNolkenGKrauseUDel PozoEBeyerJ. Somatostatin analogue SMS 201–995 in type I diabetes mellitus. Scand J Gastroenterol1986; 21 (suppl): 166–9.
15.
MillerR. Nail dystrophy following intralesional injections of bleomycin for a periungual wart (letter). Arch Dermatol1984; 120: 963–4.
16.
ShumerSO'KeefeE. Bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol1983; 9: 91–6.
17.
ShumackPHaddockM. Bleomycin: An effective treatment for warts. Aust J Derm1979; 20: 41–2.
18.
AmerMDiabNRamadaAGalalASalemA. Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts. J Am Acad Dermatol1988; 18: 1313–6.
19.
AbbottL. Treatment of warts with bleomycin. Aust J Derm1978; 19: 69–71.
20.
CordanoAGuglielmiHWoscoffA. The common wart: Intralesional treatment with bleomycin sulfate. Cutis1980; 26: 319–24.
21.
HayesMO'KeefeE. Reduced dose of bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol1986; 15: 1002–6.
22.
MunkvadMGennerJStabergBKingsholmH. Locally injected bleomycin in the treatment of warts. Dermatologica1983; 167: 86–9.
23.
GonzalezFCristobalMMartinezARodriguezPDe PazF SanchezGarcia-PerezA. Cutaneous toxicity of intralesional bleomycin administration in the treatment of periungual warts. Arch Dermatol1986; 122: 974–5.
24.
EpsteinE. Persisting Raynaud's phenomenon following intralesional bleomycin treatment of finger warts (letter). J Am Acad Dermatol1985; 13: 468–71.
25.
BovenmeyerDA. Persisting Raynaud's phenomenon following intralesional treatment of finger warts (letter). J Am Acad Dermatol1985; 13: 470–1.
26.
SmithEAHarberFELeroyEG. Raynaud's phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum1985; 28: 459–61.
27.
VogelzangNJBoslGJJohnsonKKennedyBJ. Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med1981; 95: 288–92.
28.
AdoueDArletP. Bleomycin and Raynaud's phenomenon (letter). Ann Intern Med1984; 100: 770.
